Hepatitis Research and Treatment Center

The Hepatitis Research and Treatment Center, under the direction of Dr. Karen L. Lindsay, offers continuous screening opportunities for patients for treatment trials using new drug therapies for hepatitis B and C. For more information about clinical trials, contact the Hepatitis Research and Treatment Center at 323-224-5555.

The Hepatitis Research and Treatment Center is located in the Health Research Association Building, located off of the Santa Ana Freeway (5) at the Mission Street exit, on the corner of Marengo and Mission.

Current Clinical Trials

Vertex 108

The Vertex 108 study a phase 3 hepatitis C study using Telaprevir in combination with peginterferon alfa-2a and ribavirin in treatment-naïve subjects with genotype 1.

If you would like to refer a patient, please call the coordinators, Carol Jones, RN or Susan Milstein, RN, BSN at 323-224-5555 at the USC Hepatitis Research and Treatment Center.

Wyeth HCV-796

THIS STUDY IS CLOSED TO ACCRUAL

The Wyeth HCV-796 study is a phase 2, randomized, open label study of the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with PEG-Intron plus REBETOL versus PEG-intron plus REBETOL in HCV genotype 1-infected subjects who are either naïve to treatment or who have previously failed treatment (non-responder). The primary objective is to assess the safety and tolerability, as well as antiviral activity, of HCV-796 when administered in combination with PEG-intron plus REBETOL versus PEG-intron plus REBETOL in treatment –naïve or non responder subjects with HCV genotype 1 infection.

If you would like to refer a patient, please call the coordinators, Carol Jones RN or Susan Milstein RN BSN at 323-224-5555 at the USC Hepatitis Research and Treatment Center.

HGS ACHIEVE 1

THIS STUDY IS CLOSED TO ACCRUAL

The HGS ACHIEVE 1 is a phase 3 study evaluating the safety and effectiveness of Albumin interferon alfa-2b (alb-IFN) in combination with ribavirin versus PEGASYS in combination with ribavirin.

If you would like to refer a patient, please call the coordinators, Carol Jones RN or Susan Milstein RN BSN at 323-224-5555 at the USC Hepatitis Research and Treatment Center.

HALT-C

THIS STUDY IS CLOSED TO ACCRUAL

The HALT-C Trial is a multi-center, randomized controlled study designed to determine if continuing interferon long term over several years will suppress the hepatitis C virus, prevent progression to cirrhosis, prevent liver cancer and reduce the need for liver transplantation.

You may contact the Hepatitis Research and Treatment Center by sending an e-mail to hepinfo@usc.edu, by calling (323) 224-5555 or faxing (323) 224-5465), or by writing to the address noted below.

Hepatitis Research and Treatment Center
Keck School of Medicine
University of Southern California
1640 Marengo Street, Suite 103
Los Angeles, CA 90033